![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: CDKN2B-AS1 |
Gene summary for CDKN2B-AS1 |
![]() |
Gene information | Species | Human | Gene symbol | CDKN2B-AS1 | Gene ID | 100048912 |
Gene name | CDKN2B antisense RNA 1 | |
Gene Alias | ANRIL | |
Cytomap | 9p21.3 | |
Gene Type | ncRNA | GO ID | GO:0006928 | UniProtAcc | NA |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
100048912 | CDKN2B-AS1 | HCC1_Meng | Human | Liver | HCC | 4.22e-78 | 6.52e-01 | 0.0246 |
100048912 | CDKN2B-AS1 | S027 | Human | Liver | HCC | 2.57e-02 | 1.70e-01 | 0.2446 |
100048912 | CDKN2B-AS1 | S028 | Human | Liver | HCC | 3.07e-19 | 6.74e-01 | 0.2503 |
100048912 | CDKN2B-AS1 | S029 | Human | Liver | HCC | 7.77e-16 | 8.85e-01 | 0.2581 |
100048912 | CDKN2B-AS1 | RNA-P17T-P17T-4 | Human | Lung | IAC | 4.28e-05 | 5.86e-01 | 0.343 |
100048912 | CDKN2B-AS1 | RNA-P17T-P17T-6 | Human | Lung | IAC | 2.66e-08 | 7.87e-01 | 0.3385 |
100048912 | CDKN2B-AS1 | RNA-P17T-P17T-8 | Human | Lung | IAC | 5.26e-09 | 6.78e-01 | 0.3329 |
100048912 | CDKN2B-AS1 | RNA-P6T2-P6T2-1 | Human | Lung | IAC | 1.39e-03 | 2.12e-01 | -0.0166 |
100048912 | CDKN2B-AS1 | RNA-P6T2-P6T2-2 | Human | Lung | IAC | 1.06e-02 | 1.51e-01 | -0.0132 |
100048912 | CDKN2B-AS1 | RNA-P7T1-P7T1-1 | Human | Lung | AIS | 2.37e-02 | 3.67e-01 | -0.0961 |
100048912 | CDKN2B-AS1 | RNA-P7T1-P7T1-4 | Human | Lung | AIS | 6.30e-03 | 3.63e-01 | -0.0809 |
Page: 1 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Thyroid | PTC | ![]() |
Thyroid | goiters | ![]() |
Thyroid | ATC | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
Page: 1 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
100048912 | CDKN2B-AS1 | NA | Antiinflammatory agents, non-steroids | 20538124 |
Page: 1 |